Research Reports | Market Assessment
June 2016

Heart Failure | Unmet Need | Chronic Heart Failure | US/EU | 2016

Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the greatest unmet needs. Furthermore, given that none of the currently available CHF treatments has proven outcome benefits in HFpEF patients, who constitute approximately 50% of CHF cases, a significant unmet need lies with this patient population. Therefore, significant clinical and commercial opportunities persist for therapies that can improve outcomes in this heterogeneous patient population.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports